GleamWall
中文EN

BSEM BioStem Technologies, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1658678 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets57.9%
Debt / equity0.00x
Current ratio0.73x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302025Q32025-09-302025Q22025-06-30
Income statement
Revenue$7.64M$7.90M$10.47M$10.96M
Cost of revenue$3.35M$3.06M$1.20M$685,177
Gross profit$4.29M$4.84M$9.27M$10.28M
R&D expense$481,189$733,616$1.96M$1.96M
SG&A expense$7.54M$6.50M$4.50M$6.87M
Operating income-$9.78M-$8.40M$1.45M$112,759
Pretax income-$11.38M-$8.97M$1.47M$177,953
Income tax$0$0$707,677$167,340
Net income-$11.38M-$8.97M$761,052$10,613
EBITDA-$9.07M-$7.71M$1.51M$173,498
EPS (basic)-0.64-0.520.050.00
EPS (diluted)-0.64-0.520.030.00
Weighted avg. shares (diluted)17.86M17.33M22.79M23.42M
Balance sheet
Cash & equivalents$971,145$6.96M$27.16M$30.84M
Receivables$6.60M$6.62M——
Inventory$6.45M$4.71M——
Current assets$16.13M$20.78M——
PP&E, net$4.38M$4.42M——
Goodwill$1.53M$1.53M——
Intangibles$20.86M$21.36M——
Total assets$43.58M$48.82M——
Current liabilities$22.17M$21.20M——
Long-term debt$0$0——
Total debt$0$0——
Total liabilities$25.25M$21.20M——
Shareholders' equity$18.33M$27.61M$49.16M$47.23M
Net debt-$971,145-$6.96M——
Shares outstanding18.68M17.84M——
Cash flow statement
Operating cash flow-$8.82M—-$2.36M—
Capital expenditure$0—$2.44M—
Free cash flow-$8.82M—-$4.80M—
Investing cash flow-$169,090—-$1.19M—
Financing cash flow$3.00M—-$135,000—
Depreciation & amortization$706,661$689,317$57,644$60,739
Stock-based compensation$1.01M$1.00M$504,787$495,874

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.